Effect of oral semaglutide on hepatic fibrosis of type 2 diabetes patients with NAFLD

Not Applicable

Not yet recruiting

• Conditions: type 2 diabetes patients with NAFLD

• Registration Number: JPRN-UMIN000046994
• Lead Sponsor: Shizuoka General Hospital, Center for Diabetes, Endocrinology and Metabolism

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-03-03
• Last Update Posted: 17 October 2023
• Study Completion: 2027-03-31

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

(1) Diabetes other than type 2 diabetes (2) Taking thiazolidine drugs (3) History of use of other GLP-1 receptor agonists (4) Patients diagnosed with liver diseases other than NAFLD such as viral hepatitis and autoimmune hepatitis (5) Allergies to semaglutide (6) Diabetic ketoacidosis, diabetic coma or precoma, type 1 diabetes (7) Serious conditions such as acute infections and surgery (8) Patients judged to be inappropriate

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
change in FIB4 index at 6 months from baseline

Secondary Outcome Measures

Name	Time	Method
change in NFS,M2BPGi,tryptophan and tryptophan metabolites and the other various parameters at 6 months from baseline